Lucemyra (lofexidine)

Indications for Prior Authorization

Lucemyra (lofexidine)
  • For diagnosis of Opioid withdrawal
    Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Criteria

Lucemyra

Step Therapy

Length of Approval: 12 Month(s)

  • Requested drug is being used for a Food and Drug Administration (FDA)-approved indication
  • AND
  • Trial and failure (of a minimum 30-day supply), contraindication, or intolerance to clonidine
P & T Revisions

2025-01-06, 2024-01-03, 2023-01-04, 2022-01-06, 2021-01-06, 2020-01-17

  1. Lucemyra Prescribing Information. USWM, LLC. Louisville, KY. September 2020.

  • 2025-01-06: 2025 Annual Review. No updates.
  • 2024-01-03: Annual review: No updates required.
  • 2023-01-04: Annual review: Updated criteria.
  • 2022-01-06: Annual review: Updated criteria and background.
  • 2021-01-06: Annual review: No updates required.
  • 2020-01-17: Annual review: no updates required.